Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 3 7Phase 2/3 4Phase NA 2Phase 1/2 1Phase 1 1

Status

Withdrawn 2Terminated 1Suspended 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Colorectal Neoplasms 7Carcinoma, Hepatocellular 4Rectal Neoplasms 2Stomach Neoplasms 1Peripheral Nervous System Diseases 1Neoplasm Metastasis 1Liver Neoplasms 1Colonic Neoplasms 1Biliary Tract Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Sorafenib 8Oxaliplatin 7Bevacizumab 6sintilimab 5lenvatinib 5apatinib 5Fluorouracil 5Capecitabine 5atezolizumab 4Leucovorin 4Folfox protocol 4camrelizumab 3Drug Therapy 3tremelimumab 2durvalumab 2Thalidomide 2Radiosurgery 2Nivolumab 2Neoadjuvant Therapy 2Injections 2Hepatectomy 2Gemcitabine 2Ethiodized Oil 2regorafenib 1pirarubicin 1pembrolizumab 1menatetrenone 1liposomal doxorubicin 1lanreotide 1halofantrine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2/3 × Carcinoma, Hepatocellular × Folfox protocol × Clear all
NCT05171166 2025-12-18

Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.

Peking University

Phase 2/3 Terminated
18 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT05033522 2025-10-23

ALIVE

Mirror Biologics, Inc.

Phase 2/3 Suspended
150 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT02527772 2019-06-04

LD-FOX4/HCC

Guangxi Medical University

Phase 2/3 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

NCT02534337 2019-06-04

Gemcitabine Plus Oxaliplatin Versus Oxaliplatin Plus Fluorouracil/Leucovorin for Hepatocellular Carcinoma

Guangxi Medical University

Phase 2/3 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡